Irish High Court hearing for Horizon's $28B sale to Amgen set for Oct. 5
Mario Tama/Getty Images News

Horizon Therapeutics (NASDAQ:HZNP) announced that the Irish High Court has set Oct. 5 for a hearing on its planned $28 billion sale to Amgen (NASDAQ:AMGN).
The Irish High Court has set the court hearing for Oct. 5 at 11 a.m. (Irish time) to consider Horizonâs application to sanction the scheme, according to a statement. 

The news comes after the Federal Trade Commission on Friday settled with Amgen (AMGN) and Horizon (HZNP) to allow the combination to move forward. The companies said they expect to be able to close the deal in the early fourth quarter.
Approval from the Irish High Court is the last remaining clearance the deal needs before it can close.
Amgen (AMGN) agreed to acquire Horizon (HZNP) for $116.50 a share in cash in December, valuing the Ireland-based biotech at nearly $27.8 billion.



More on Horizon Therapeutics

Seeking Alphaâs Quant Rating on Horizon Therapeutics
Historical earnings data for Horizon Therapeutics
Financial information for Horizon Therapeutics
Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?
Improved Outlook For Horizon Therapeutics And Amgen